Rodrigo Gularte-Mérida

Rodrigo Gularte-Mérida

Auto-generated profile, based on publicly available information

Rodrigo Gularte-Mérida

Unit of Animal Genomics, GIGA Institute and Faculty of Veterinary Medicine, University of Liège

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
BNBenjamin Nacev
Benjamin Nacev
FSFrancisco Sanchez-Vega
Francisco Sanchez-Vega
SSShaleigh A. Smith
Shaleigh A. Smith
CACristina R. Antonescu
Cristina R. Antonescu
EREvan Rosenbaum
Evan Rosenbaum
WTWilliam D. Tap
William D. Tap
The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the identification of therapeutic targets, clinical research, and advancing patient care. Because there are > 100 sarcoma subtypes, in-depth genetic studies have focused on one or a few subtypes. Herein, we report a comparative genetic analysis of 2,138 sarcomas representing 45 pathological entities. This cohort is prospectively analyzed using targeted sequencing to characterize subtype-specific somatic alterations in targetable pathways, rates of whole genome doubling, mutational signatures, and subtype-agnostic genomic clusters. The most common alterations are in cell cycle control andTP53, receptor tyrosine kinases/PI3K/RAS, and epigenetic regulators. Subtype-specific associations includeTERTamplification in intimal sarcoma and SWI/SNF alterations in uterine adenosarcoma. Tumor mutational burden, while low compared to other cancers, varies between and within subtypes. This resource will improve sarcoma models, motivate studies of subtype-specific alterations, and inform investigations of genetic factors and their correlations with treatment response.

17 November 2017 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
JKJisun Kim
Jisun Kim
FGFelipe C Geyer
Felipe C Geyer
LMLuciano G Martelotto
Luciano G Martelotto
CNCharlotte K Y Ng
Charlotte K Y Ng
RLRaymond S Lim
Raymond S Lim
BWBritta Weigelt
Britta Weigelt

4 July 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
Caterina MarchiòCaterina Marchiò
Caterina Marchiò
APArnaud Da Cruz Paula
Arnaud Da Cruz Paula
RGRodrigo Gularte-Merida
Rodrigo Gularte-Merida
TBThais Basili
Thais Basili
ABAlissa Brandes
Alissa Brandes
MPMauro Papotti
Mauro Papotti

30 March 2018 in Histopathology
Verified
Journal Article
Closed access
PDF file
JLJohn R Lozada
John R Lozada
TBThais Basili
Thais Basili
FPFresia Pareja
Fresia Pareja
BABarbara Alemar
Barbara Alemar
APArnaud Da Cruz Paula
Arnaud Da Cruz Paula
FGFelipe C Geyer
Felipe C Geyer

2 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SKSarah H. Kim
Sarah H. Kim
APArnaud Da Cruz Paula
Arnaud Da Cruz Paula
TBThais Basili
Thais Basili
HDHiginio Dopeso
Higinio Dopeso
RBRui Bi
Rui Bi
BWBritta Weigelt
Britta Weigelt
Sclerosing stromal tumor (SST) of the ovary is a rare type of sex cord-stromal tumor (SCST), whose genetic underpinning is currently unknown. Here, using whole-exome, targeted capture and RNA-sequencing, we report recurrent FHL2-GLI2 fusion genes in 65% (17/26) of SSTs and other GLI2 rearrangements in additional 15% (4/26) SSTs, none of which are detected in other types of SCSTs (n = 48) or common cancer types (n = 9,950). The FHL2-GLI2 fusions result in transcriptomic activation of the Sonic Hedgehog (SHH) pathway in SSTs. Expression of the FHL2-GLI2 fusion in vitro leads to the acquisition of phenotypic characteristics of SSTs, increased proliferation, migration and colony formation, and SHH pathway activation. Targeted inhibition of the SHH pathway results in reversal of these oncogenic properties, indicating its role in the pathogenesis of SSTs. Our results demonstrate that the FHL2-GLI2 fusion is likely the oncogenic driver of SSTs, defining a genotypic–phenotypic correlation in ovarian neoplasms.

8 August 2019 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
ALAnqi Li
Anqi Li
FGFelipe C. Geyer
Felipe C. Geyer
PBPedro Blecua
Pedro Blecua
JLJu Youn Lee
Ju Youn Lee
PSPier Selenica
Pier Selenica
Jorge S. Reis-FilhoJorge S. Reis-Filho
Jorge S. Reis-Filho
Mono-allelic germline pathogenic variants in the Partner And Localizer of BRCA2 (PALB2) gene predispose to a high-risk of breast cancer development, consistent with the role of PALB2 in homologous recombination (HR) DNA repair. Here, we sought to define the repertoire of somatic genetic alterations in PALB2-associated breast cancers (BCs), and whether PALB2-associated BCs display bi-allelic inactivation of PALB2 and/or genomic features of HR-deficiency (HRD). Twenty-four breast cancer patients with pathogenic PALB2 germline mutations were analyzed by whole-exome sequencing (WES, n = 16) or targeted capture massively parallel sequencing (410 cancer genes, n = 8). Somatic genetic alterations, loss of heterozygosity (LOH) of the PALB2 wild-type allele, large-scale state transitions (LSTs) and mutational signatures were defined. PALB2-associated BCs were found to be heterogeneous at the genetic level, with PIK3CA (29%), PALB2 (21%), TP53 (21%), and NOTCH3 (17%) being the genes most frequently affected by somatic mutations. Bi-allelic PALB2 inactivation was found in 16 of the 24 cases (67%), either through LOH (n = 11) or second somatic mutations (n = 5) of the wild-type allele. High LST scores were found in all 12 PALB2-associated BCs with bi-allelic PALB2 inactivation sequenced by WES, of which eight displayed the HRD-related mutational signature 3. In addition, bi-allelic inactivation of PALB2 was significantly associated with high LST scores. Our findings suggest that the identification of bi-allelic PALB2 inactivation in PALB2-associated BCs is required for the personalization of HR-directed therapies, such as platinum salts and/or PARP inhibitors, as the vast majority of PALB2-associated BCs without PALB2 bi-allelic inactivation lack genomic features of HRD.